Mixed MOR/DOR Agonist Activity Provides Improved Analgesic Efficacy and Tolerability for the Treatment of Pathological Pain States Including Pain-Induced Adaptive Changes in the Nervous System

Technology #ua17-102

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Yeon Sun Lee
Research Assistant Professor, Chemistry & Biochemistry
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Frank Porreca
Professor, Pharmacology
Managed By
Lisa Lin
Licensing Manager (520) 626-6969

Title: Mixed MOR/MOD Agonist Activity Provides Improved Analgesic Efficacy and Tolerability for the Treatment of Pathological Pain States Including Pain-Induced Adaptive Changes in the Nervous System

 

Invention: The invention is the discovery of lead ligands, LYS739 and LYS744, for the treatment of chronic pain including neuropathic pain. These are single compounds representing a novel therapeutic pathway to improve analgesic efficacy.

 

Background: Chronic pain is poorly managed with current medications because long term administration or higher doses may increase the potential for addiction and adverse effects such as respiratory depression. Chronic pain is known to up-regulate kappa opioid receptors, causing a diminished analgesic effect from mu opioid receptor agonists. A single molecule with the ability to target multiple opioid receptors would allow the use for lower doses and decrease adverse effects.

 

Applications:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic assay companies
  • Research centers
  • Academic laboratories

 

Advantages:

  • High efficacy
  • Reduces adverse effects
  • Able to penetrate blood brain barrier
  • Improves bioavailability with lipophilic moiety

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-2687